Salarius Pharmaceuticals Inc (SLRX NASDAQ) stock market data APIs
$5.4735
-0.11(-2%)
as of September 15, 2025
Try our APIs with
free plan!
Salarius Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Salarius Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is based in Houston, Texas.
Prev. Close
5.4735
Open
5.3625
High
5.6359
Low
4.834
52 wk Range
4.5-55.05
Market Cap
2 696 K
Shares Outstanding
510 K
EPS
-0.45
Beta
0.501
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Salarius Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Salarius Pharmaceuticals Inc data using free add-ons & libraries
Get Salarius Pharmaceuticals Inc Fundamental Data
Salarius Pharmaceuticals Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -5 675 021
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: -1.02
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Salarius Pharmaceuticals Inc News
New
Salarius Pharmaceuticals regains compliance with Nasdaq minimum bid price requirement
* Salarius Pharmaceuticals (NASDAQ:SLRX [https://seekingalpha.com/symbol/SLRX]) on Tuesday said it has received notification from Nasdaq that it has regained compliance with the Minimum Bid Price Re...
Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
HOUSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on September 4, 2025 the Company received notification from The Nas...
Get insights into the top gainers and losers of Tuesday's after-hours session.
After the conclusion of the US market's regular session on Tuesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. [postmarket] TODAY'S AFT...
Salarius Pharmaceuticals To Implement 1-for-15 Reverse Stock Split
(RTTNews) - Salarius Pharmaceuticals, Inc. (SLRX), a clinical-stage biopharmaceutical company, Thursday announced that it will implement a 1-for-15 reverse stock split effective August 15. Trading on...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
